Lu Han
Impact in
- Oncology top 5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunology top 10%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Papers in
- Oncology 24
- CAR-T cell therapy research 19
- Cancer Immunotherapy and Biomarkers 9
- Immunology 16
- Immunotherapy and Immune Responses 8
- Immune Cell Function and Interaction 7
- Galectins and Cancer Biology 3
- Co-authors
- Wenyan Jiang (2 shared papers)Yahong Luo (2 shared papers)Jie Tian (2 shared papers)Di Dong (2 shared papers)Jing Cui (12 shared papers)Quanli Gao (9 shared papers)Jian Wang (1 shared paper)Jishuai Zhang (8 shared papers)
- Journals
- Frontiers in Immunology (6 papers)Blood (3 papers)Veterinary Research (3 papers)Frontiers in Oncology (3 papers)Cancer Immunology Immunotherapy (2 papers)
- Partner nations
- ChinaUnited StatesItaly
In The Last Decade
Lu Han
59 papers receiving 1.5k citations
Lu Han's Hit Papers
Peers
Comparison fields: 5 of 88
- Oncology 629
- Immunology 373
- Radiology, Nuclear Medicine and Imaging 161
- Obstetrics and Gynecology 47
- Infectious Diseases 116
Countries citing papers authored by Lu Han
This map shows the geographic impact of Lu Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Han more than expected).
Fields of papers citing papers by Lu Han
This network shows the impact of papers produced by Lu Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Han. The network helps show where Lu Han may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Han, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Hit paper breakdown → | 2021 | 214 |
| 2 | 2019 | 155 | |
| 3 | 2017 | 124 | |
| 4 | 2018 | 88 | |
| 5 | 2021 | 87 | |
| 6 | 2018 | 81 | |
| 7 | 2015 | 69 | |
| 8 | 2022 | 51 | |
| 9 | 2020 | 48 | |
| 10 | 2022 | 46 | |
| 11 | 2023 | 42 | |
| 12 | 2022 | 37 | |
| 13 | 2021 | 34 | |
| 14 | 2017 | 33 | |
| 15 | 2020 | 30 | |
| 16 | 2022 | 30 | |
| 17 | 2021 | 29 | |
| 18 | 2021 | 23 | |
| 19 | 2019 | 20 | |
| 20 | 2022 | 19 |
About Lu Han
Lu Han is a scholar working on Oncology, Immunology, Molecular Biology, Infectious Diseases and Pulmonary and Respiratory Medicine, having authored 59 papers that have together received 1.5k indexed citations. Recurring topics across this work include CAR-T cell therapy research (19 papers), Cancer Immunotherapy and Biomarkers (9 papers), Parasitic Diseases Research and Treatment (9 papers), Immunotherapy and Immune Responses (8 papers), Immune Cell Function and Interaction (7 papers), Parasites and Host Interactions (5 papers), Parasite Biology and Host Interactions (5 papers) and Galectins and Cancer Biology (3 papers). The work is most often cited by research in Oncology (629 citations), Immunology (373 citations), Radiology, Nuclear Medicine and Imaging (161 citations), Obstetrics and Gynecology (47 citations) and Infectious Diseases (116 citations). Lu Han has collaborated with scholars based in China, United States and Italy. Frequent co-authors include Wenyan Jiang, Yahong Luo, Jie Tian, Di Dong, Jing Cui, Quanli Gao, Jian Wang, Jishuai Zhang, Xu Shu and Zhong Quan Wang. Their work appears in journals such as Frontiers in Immunology, Blood, Veterinary Research, Frontiers in Oncology and Cancer Immunology Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.